SYLENTIS Trademark

Trademark Overview

On Wednesday, May 18, 2022, a trademark application was filed for SYLENTIS with the United States Patent and Trademark Office. The USPTO has given the SYLENTIS trademark a serial number of 97417038. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Monday, November 6, 2023. This trademark is owned by SYLENTIS, S.A.U.. The SYLENTIS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Ophthalmologic preparations for the treatment of ocular disorders or diseases; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of ocular disorders or diseases; collyrium; ophthalmic preparations; medicated gels, creams and washing solutions for eye use; medicated eye drops; medicated eye lotions; medicated eye sprays; medicated eye ointments for treating dry eye, ocular pain and conjunctivitis; all the foregoing excluding those comprising isotopes or compounds labelled with stable isotopes

Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development of pharmaceutical preparations and medicines; Pharmaceutical product evaluation; Research in the field of pharmaceuticals; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Development of pharmaceutical preparations and medicines for the treatment of eye diseases and conditions; Development of pharmaceutical preparations and medicines for the treatment of ocular disorders or diseases; Testing, inspection, research, or development of pharmaceutical preparations for the treatment of eye diseases and conditions; Testing, inspection, research, or development of pharmaceutical preparations for the treatment of ocular disorders or diseases; all the foregoing excluding isotope labelling and diagnostics
sylentis

General Information

Serial Number97417038
Word MarkSYLENTIS
Filing DateWednesday, May 18, 2022
Status645 - FINAL REFUSAL - MAILED
Status DateMonday, November 6, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesOphthalmologic preparations for the treatment of ocular disorders or diseases; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of ocular disorders or diseases; collyrium; ophthalmic preparations; medicated gels, creams and washing solutions for eye use; medicated eye drops; medicated eye lotions; medicated eye sprays; medicated eye ointments for treating dry eye, ocular pain and conjunctivitis; all the foregoing excluding those comprising isotopes or compounds labelled with stable isotopes
Goods and ServicesConsulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development of pharmaceutical preparations and medicines; Pharmaceutical product evaluation; Research in the field of pharmaceuticals; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Development of pharmaceutical preparations and medicines for the treatment of eye diseases and conditions; Development of pharmaceutical preparations and medicines for the treatment of ocular disorders or diseases; Testing, inspection, research, or development of pharmaceutical preparations for the treatment of eye diseases and conditions; Testing, inspection, research, or development of pharmaceutical preparations for the treatment of ocular disorders or diseases; all the foregoing excluding isotope labelling and diagnostics

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, May 24, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, May 24, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSYLENTIS, S.A.U.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressMadrid E-28003
ES

Trademark Events

Event DateEvent Description
Monday, November 6, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, November 6, 2023FINAL REFUSAL E-MAILED
Monday, November 6, 2023FINAL REFUSAL WRITTEN
Wednesday, September 20, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, September 19, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 19, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, June 20, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, June 20, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, March 20, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 20, 2023NON-FINAL ACTION E-MAILED
Monday, March 20, 2023NON-FINAL ACTION WRITTEN
Tuesday, March 7, 2023ASSIGNED TO EXAMINER
Tuesday, May 24, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, May 21, 2022NEW APPLICATION ENTERED

Related Keywords

sylentis preparations pharmaceutical treatment diseases development ocular medicated research disorders inspection